DNMT3A and temporal lobe epilepsy: In the present study, we established a model of temporal lobe epilepsy in rats characterized by SRS following pilocarpine–induced status epilepticus and initiated VNS therapy at stage of epileptogenesis (development of an epileptic condition, the 4th week after pilocarpine injection), and demonstrated VNS inhibition remarkable of the overexpression of DNMT1 and DNMT3A in epileptic rats (Figure 2).